Sessioni Comunicazioni Orali
KETAMINE AND PHARMACOLOGY OF PSHYCHIATRIC DISEASES
28/10/2017 / 9.00 - 11.00
| 60 | KETAMINE INDUCED STRUCTURAL PLASTICITY IN HUMAN IPSC-DERIVED DOPAMINERGIC NEURONS 1)Collo G.. 2)Cavalleri L.. 3)Millan MJ. 4)Chiamulera C.. 5)Spano PF. 6)Merlo pich E.. |
| 61 | POST-SYNAPTIC GLUTAMATE DYSFUNCTION INDUCED BY KETAMINE SELF-ADMINISTRATION 1)Caffino L. 2)Piva A. 3)Mottarlini F. 4)Giannotti G. 5)Di chio M. 6)Venniro M. 7)Yew DT. 8)Chiamulera C. 9)Fumagalli F. |
| 62 | METAPLASTIC TREATMENTS WITH KETAMINE AND MK-801 AFFECT INSTRUMENTAL APPETITIVE MEMORY RECONSOLIDATION IN RATS 1)Gerace E. 2)Piva A. 3)Di chio M. 4)Padovani L. 5)Pellegrini-giampietro DE. 6)Chiamulera C. |
| 63 | THE MULTIPLE EFFECTS OF THE KETAMINE ANALOG METHOXETAMINE: PRECLINICAL EVIDENCE 1)Fattore L. 2)Zanda MT. 3)Mutti A. 4)Fratta W. 5)Chiamulera C. |
| 64 | Ketamine modulation of PSD gene expression: implication for pathophysiology and treatment of behavioral disorders |
| 65 | Dopamine D3 receptors control dysbindin-dependent executive functions alterations relevant to schizophrenia 1)Leggio GM. 2)Torrisi SA. 3)Managò F. 4)Chisari M. 5)Mastrogiacomo R. 6)Mereu M. 7)De luca MA. 8)Ciranna L. 9)Salomone S. 10)Drago F. 11)Papaleo F. |
| 66 | Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: role of 5-HT2A receptor agonism 1)Scarselli M. 2)Aringhieri S. 3)Kolachalam S. 4)Carli M. |
| 67 | EFFECTS OF THE PPAR-ALPHA AGONIST FENOFIBRATE IN AN IMMUNE-MEDIATED NEURODEVELOPMENTAL MODEL OF PSYCHOSIS 1)Pistis M. 2)Sagheddu C. 3)Aroni S. 4)Muntoni AL. 5)Frau R. 6)Fanni S. 7)Pardu A. 8)Devoto P. 9)Melis M. 10)De felice M. |
| 68 | A precision medicine genetic marker for core cognitive deficits in schizophrenia 1)Scheggia D. 2)Mastrogiacomo R. 3)Mereu M. 4)Sannino S. 5)Straub RE. 6)Armando M. 7)Managò F. 8)Piras F. 9)De luca MA. 10)Weinberger DR. 11)Spalletta G. 12)Papaleo F. |